Minerva Neurosciences, Inc. (NERV) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Minerva Neurosciences, Inc. (NERV) closed at USD 2.35 on 2026-10-14, a change of -48.9 % over the past year, with a market capitalization of USD 115.55M.

Minerva Neurosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Minerva Neurosciences, Inc. key figures

Previous close

USD 2.35 (2026-10-14)

1-year change

-48.9 %

Market cap

USD 115.55M

Enterprise value

USD 112.02M

P/E ratio (trailing)

-0.07

P/E ratio (forward)

-5.76

EPS (trailing)

-34.61

EPS (forward)

-0.42

PEG ratio

n/a

Price to book

-0.54

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

15.60

Employees

7

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Minerva Neurosciences, Inc. and compare it with other stocks.